Literature DB >> 15328104

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

David A Stevens1, Marife Espiritu, Rachana Parmar.   

Abstract

Resistance problems with caspofungin, an echinocandin inhibitor of fungal cell wall glucan synthesis, have been rare. We noted paradoxical turbid growth of Candida albicans isolates in broth in some high (supra-MIC) concentrations. Among isolates submitted for susceptibility testing and screened at drug concentrations up to 12.5 microg/ml, the frequency was 16%. Analysis of the turbid growth indicated slowing of growth in the presence of drug but with numbers of CFU up to 72% those of drug-free controls. Clearing of growth again by the highest drug concentrations produced a quadriphasic pattern in a tube dilution series. Cells growing at high drug concentrations were not resistant on retesting but showed the paradoxical effect of the parent. Among a selected series of isolates tested at concentrations up to 50 microg/ml, an additional 53% showed a "mini-paradoxical effect": no turbid growth but incomplete killing at high concentrations (supra-minimum fungicidal concentration). These effects were reproducible; medium dependent in extent; noted in macro- and microdilution, in the presence or absence of serum, and on agar containing drug (but not when drug concentrations were not constant, as in agar diffusion); not seen with other echinocandins and less commonly in other Candida species; and not due to destruction of drug in tubes showing the effect. Cooperative enhancement of inhibition by a second drug could eradicate the effect. We postulate that high drug concentrations derepress or activate resistance mechanisms. The abilities of subpopulations to survive at high drug concentrations could have in vivo consequences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328104      PMCID: PMC514730          DOI: 10.1128/AAC.48.9.3407-3411.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Molecular epidemiology of the global and temporal diversity of Candida albicans.

Authors:  M J McCullough; K V Clemons; D A Stevens
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

2.  Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control.

Authors:  N Kondo; K Kuwahara-Arai; H Kuroda-Murakami; E Tateda-Suzuki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model.

Authors:  David A Stevens; Leilani Calderon; Martha Martinez; Karl V Clemons; Shelly J Wilson; Claude P Selitrennikoff
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

Review 4.  High-frequency switching in Candida albicans.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Obfuscation of the activity of antifungal antimicrobics by culture media.

Authors:  P D Hoeprich; P D Finn
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

6.  Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.

Authors:  K A Marr; C N Lyons; K Ha; T R Rustad; T C White
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Susceptibility of Candida albicans to flucytosine when tested in different formulations of yeast nitrogen base broth.

Authors:  J N Galgiani; C A Yturralde; K O Dugger
Journal:  Diagn Microbiol Infect Dis       Date:  1986-09       Impact factor: 2.803

8.  The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.

Authors:  H EAGLE; A D MUSSELMAN
Journal:  J Exp Med       Date:  1948-07       Impact factor: 14.307

9.  Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.

Authors:  John R Graybill; Rosie Bocanegra; Laura K Najvar; Steve Hernandez; Robert A Larsen
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus.

Authors:  C Bartizal; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  89 in total

1.  Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.

Authors:  Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-26       Impact factor: 4.799

Review 2.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

3.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 4.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

5.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.

Authors:  Vânia Lúcia Ribeiro da Matta; Márcia de Souza Carvalho Melhem; Arnaldo Lopes Colombo; Maria Luiza Moretti; Laura Rodero; Gisele Madeira Duboc de Almeida; Marilena dos Anjos Martins; Silvia Figueiredo Costa; Maria Beatriz G Souza Dias; Márcio Nucci; Anna S Levin
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

7.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

8.  Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.

Authors:  Aspasia Katragkou; Athanasios Chatzimoschou; Maria Simitsopoulou; Maria Dalakiouridou; Eudoxia Diza-Mataftsi; Chaido Tsantali; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

9.  Frequency of paradoxical effect with caspofungin in Candida albicans.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

10.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.